Literature DB >> 20068362

Investigation of the use of antioxidants to diminish the adverse effects of postnatal glucocorticoid treatment on mortality and cardiac development.

Alexandra Adler1, Emily J Camm, Jeremy A Hansell, Hans G Richter, Dino A Giussani.   

Abstract

BACKGROUND: In premature infants, glucocorticoids ameliorate chronic lung disease, but have adverse effects on growth and the cardiovascular system. Glucocorticoid excess promotes free radical overproduction and vascular dysfunction.
OBJECTIVES: We hypothesized that the adverse effects of postnatal glucocorticoid therapy are secondary to oxidative stress and that antioxidant treatment would diminish unwanted effects.
METHODS: Male rat pups received a clinically relevant course of dexamethasone (Dex), or Dex with vitamins C and E (DexCE), on postnatal days 1-6 (P1-6). Controls received saline (Ctrl) or saline with vitamins (CtrlCE).
RESULTS: At P21, Dex reduced survival (Ctrl: 96 vs. Dex: 70%) and promoted asymmetric growth restriction (ponderal index, Ctrl: 6.3 +/- 0.1 g . mm(-3) x 10(-5) vs. Dex: 7.4 +/- 0.2 g . mm(-3) x 10(-5)), both p < 0.05. Dex increased cardiac oxidative stress (protein expression: 4-HNE +20%, Hsp90 -42% and eNOS -54%), induced left ventricle (LV) wall thinning (LV wall volume: Ctrl: 47.2 +/- 1.2 mm(3) vs. Dex: 38.9 +/- 1.7 mm(3)) and decreased the ratio of the aortic lumen:total vessel area (Ctrl: 0.74 +/- 0.01 vs. Dex: 0.66 +/- 0.02), all p < 0.05. DexCE restored towards control values survival, growth symmetry the aortic lumen:total vessel area, and increased the cardiac expression of Hsp90 relative to Dex. In addition, relative to controls, the decrease in the cardiac expression of eNOS was no longer significant in DexCE animals (-20.3 +/- 14.4%, p > 0.05). However, DexCE did not prevent growth retardation, cardiac 4-HNE upregulation (DexCE: +29%) or LV thinning (DexCE: 40.1 +/- 1.1 mm(3)). Treatment of neonates with vitamins alone affected somatic growth and promoted thinner LV walls (CtrlCE: 39.9 +/- 0.5 mm(3), p < 0.05).
CONCLUSIONS: Combined glucocorticoid and antioxidant therapy in premature infants may be safer than glucocorticoids alone in the treatment of chronic lung disease. However, antioxidant therapy in healthy offspring is not recommended.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20068362     DOI: 10.1159/000275561

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  7 in total

1.  Steroids and antioxidants: a neonatal cocktail for saving your adult heart?

Authors:  Laura Bennet
Journal:  J Physiol       Date:  2013-10-15       Impact factor: 5.182

Review 2.  Early developmental conditioning of later health and disease: physiology or pathophysiology?

Authors:  M A Hanson; P D Gluckman
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

3.  Corticosteroid Receptors in Cardiac Health and Disease.

Authors:  Jessica R Ivy; Gillian A Gray; Megan C Holmes; Martin A Denvir; Karen E Chapman
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

4.  Oxidative stress in the developing brain: effects of postnatal glucocorticoid therapy and antioxidants in the rat.

Authors:  Emily J Camm; Deodata Tijsseling; Hans G Richter; Alexandra Adler; Jeremy A Hansell; Jan B Derks; Christine M Cross; Dino A Giussani
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

5.  Antioxidant treatment improves neonatal survival and prevents impaired cardiac function at adulthood following neonatal glucocorticoid therapy.

Authors:  Youguo Niu; Emilio A Herrera; Rhys D Evans; Dino A Giussani
Journal:  J Physiol       Date:  2013-08-12       Impact factor: 5.182

Review 6.  Glucocorticoids, antenatal corticosteroid therapy and fetal heart maturation.

Authors:  Emma J Agnew; Jessica R Ivy; Sarah J Stock; Karen E Chapman
Journal:  J Mol Endocrinol       Date:  2018-05-02       Impact factor: 5.098

7.  Isolating adverse effects of glucocorticoids on the embryonic cardiovascular system.

Authors:  Noor E W D Teulings; Tessa A C Garrud; Youguo Niu; Katie L Skeffington; Christian Beck; Nozomi Itani; Fiona G Conlon; Kimberley J Botting; Lisa M Nicholas; Thomas J Ashmore; Heather L Blackmore; Wen Tong; Emily J Camm; Jan B Derks; Angela Logan; Michael P Murphy; Susan E Ozanne; Dino A Giussani
Journal:  FASEB J       Date:  2020-06-05       Impact factor: 5.834

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.